Skip to main content
Article thumbnail
Location of Repository

Prostate cancer stem cells

By SH Lang, FM Frame and AT Collins

Abstract

Despite the discovery over 60 years ago by Huggins and Hodges 1 that prostate cancers respond to androgen deprivation therapy, hormone-refractory prostate cancer remains a major clinical challenge. There is now mounting evidence that solid tumours originate from undifferentiated stem cell-like cells coexisting within a heterogeneous tumour mass that drive tumour formation, maintain tumour homeostasis and initiate metastases. This review focuses upon current evidence for prostate cancer stem cells, addressing the identification and properties of both normal and transformed prostate stem cells

Topics: Invited Review
Publisher: John Wiley & Sons, Ltd.
OAI identifier: oai:pubmedcentral.nih.gov:2673349
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (1987). Achtst¨ atter T. Immunohistochemical investigation of different cytokeratins and vimentin in the prostate from the fetal period up to adulthood and in prostate carcinoma. Pathol Res Pract
    2. Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology 1988;122:552–562.
    3. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma.
    4. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer.
    5. (1998). Androgen receptor gene and hormonal therapy failure of prostate cancer.
    6. Androgen receptor mutations in androgenindependent prostate cancer. Cancer and Leukemia group B study,
    7. Asymmetric and symmetric stem-cell divisions in development and cancer.
    8. Asymmetric inheritance of mother versus daughter centrosome in stem cell division.
    9. ATM activation is accompanied with earlier stages of prostate tumorigenesis.
    10. (1999). Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res
    11. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway.
    12. (2004). Cellular repair of oxidatively induced base lesions is defective in prostate cancer cell lines PC-3 and Du145. Carcinogenesis
    13. (2008). Characterization of adult prostatic progenitor/stem cells exhibiting self-renewal and multilineage differentiation. Stem Cells
    14. Characterization of TMPRSS2–ETS gene aberrations in androgen-independent metastatic prostate cancer.
    15. Chromosome studies on normal and leukemic human leukocytes.
    16. (1989). Co-inoculation of tumorigenic rat prostate mesenchymal cells with non-tumorigenic epithelial cells results in the development of carcinosarcoma in syngeneic and athymic animals.
    17. Collins AT. CD133, a novel marker for human prostatic epithelial stem cells.
    18. (1992). Colocalization of basal and luminal cell-type cytokeratins in human prostate cancer. Cancer Res
    19. (2009). Control of cell proliferation and cell death in the normal and neoplastic prostate: a stem cell model. In Benign Prostatic Hyperplasia,
    20. (2001). Control of stem cell self-renewal in Drosophila spermatogenesis by JAK–STAT signalling.
    21. CXCR4–SDF-1 signalling, locomotion, chemotaxis and adhesion.
    22. (1987). Cytokeratin characterisation of human prostatic carcinoma and its derived cell lines. Cancer Res
    23. Defective DNA strand break repair after DNA damage in prostate cancer cells: implications for genetic instability and prostate cancer progression.
    24. (2000). Demonstration of intermediate cells during human prostate epithelial differentiation in situ and in vitro using triple-staining confocal scanning microscopy. Lab Invest
    25. Differential cytokeratin expression in normal hyperplastic and malignant epithelial cells from human prostate. JU r o l 1990;143:167–171.
    26. DNA damage signaling guards against activated oncogenes and tumour progression.
    27. DNA mismatch repair enzyme activity and gene expression in prostate cancer.
    28. (1990). Embryology and postnatal development of the prostate.
    29. (2006). Emerging cancer therapeutic opportunities target DNA-repair systems Trends Pharmacol Sci
    30. (1995). Endocrine–paracrine cell types in the prostate and prostatic adenocarcinoma are postmitotic cells. Hum Pathol
    31. Estrogen-dependent signalling in a molecularly distinct subclass of aggressive prostate cancer.
    32. (1999). Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Res
    33. (1996). Evidence of stem cells in the adult prostatic epithelium based upon responsiveness to mesenchymal inductors.
    34. (2001). Experimental prostate epithelial morphogenesis in response to stroma and three-dimensional Matrigel culture. Cell Growth Diff
    35. (1991). Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells.
    36. Formation of human prostate tissue from embryonic stem cells.
    37. Gene expression profiling of human prostate cancer stem cells reveals a pro-inflammatory phenotype and the importance of extracellular matrix interactions.
    38. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response.
    39. Heterogeneous expression and functions of androgen receptor co-factors in primary prostate cancer.
    40. (2006). Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene
    41. Hodges CV. Studies on prostate cancer: the effects of castration on advanced carcinoma of the prostate gland. Arch Surg 1941;43:209–223.
    42. Homologous recombination and prostate cancer: a model for novel DNA repair targets and therapies.
    43. (1997). Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med
    44. Human prostate epithelial cell-type cDNA libraries and prostate expression patterns.
    45. Identification and isolation of human prostate epithelial stem cells based on α2β1-integrin expression.
    46. Identification of CD133-positive radioresistant cells in atypical teratoid/rhabdoid tumor.
    47. (1990). Immunohistochemical localisation of the androgen receptor in rat and human tissues. Endocrinology
    48. Integrindependent anchoring of a stem-cell niche. N a tC e l lB i o l 2007;9:1413–1418.
    49. Jer´ onimo C. TMPRSS2–ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions.
    50. (2006). Maintenance of the hematopoietic stem cell pool by CXCL12–CXCR4 chemokine signalling in bone marrow stromal cell niches. Immunity
    51. (1989). Mesenchymal–epithelial interactions in the growth and development of the prostate. Cancer Treat Res
    52. (1986). Morphogenesis of ductal networks in the mouse prostate. Biol Reprod
    53. (1983). Morphologic and endocrine aspects of prostatic function.
    54. (1991). Most primitive hematopoietic stem cells are stimulated to cycle rapidly after treatment with 5-fluorouracil. Blood
    55. Notch signaling is required for normal prostatic epithelial cell proliferation and differentiation.
    56. Oncol 2003;21:2673–2678. 4 .C h e n C D ,W e l s b i e D S ,T r a n C ,B a e k
    57. Orientation of asymmetric stem cell division by the APC tumor suppressor and centrosome.
    58. p63 is a prostate basal cell marker and is required for prostate development.
    59. (1999). p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development.
    60. p63 regulates commitment to the prostate cell lineage.
    61. (2003). Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol
    62. Prevalent mutations in prostate cancer.
    63. Progression of prostate cancer by synergy of AKT with genotropic and nongenotropic actions of the androgen receptor.
    64. (2001). Proliferative heterogeneity in the human prostate: evidence for epithelial stem cells. Lab Invest
    65. Prospective identification of tumorigenic prostate cancer stem cells.
    66. Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo.
    67. (1998). Prostate stem cell compartments. Expression of the cell cycle inhibitor p27kip1 in normal, hyperplastic, and neoplastic cells.
    68. (2003). Prostate-specific deletion of the murine Pten tumour-suppressor gene leads to metastatic prostate cancer. Cancer Cell
    69. Proximal location of mouse prostate epithelial stem cells: a model of prostatic homeostasis. JC e l lB i o l 2002;157:1257–1265.
    70. Pten deletion leads to the expansion of a prostatic stem/progenitor subpopulation and tumour initiation.
    71. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.
    72. Response of glandular versus basal rat ventral prostate epithelial cells to androgen withdrawal and replacement.
    73. Role of the intracellular domains of CXCR4 in SDF-1-mediated signalling.
    74. Role of the TMPRSS2–ERG gene fusion in prostate cancer.
    75. SDF-1 tells stem cells to mind their Ps and Zs.
    76. Spradling AC. 2007;The male and female Drosophila germline stem cell niches: two versions of immortality.
    77. (2009). Stem cell differentiation within the human prostate epithelium: implications for prostate carcinogenesis.
    78. Stem cell niche: structure and function.
    79. Stem cell self-renewal specifed by JAK–STAT activation in response to a support cell cue.
    80. Stem cell-related ‘self-renewal’ signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma.
    81. Stromal cell-derived factor-1 (SDF-1) signalling regulates human placental trophoblast cell survival.
    82. Targeting DNA repair as a promising approach in cancer therapy.
    83. TGF-β maintains dormancy of prostatic stem cells in the proximal region of ducts. JC e l lB i o l2005;170(1):81–90.
    84. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype.
    85. The Drosophila ovarian and testis stem cell niches: similar somatic cells and signals.
    86. (1966). The fine structure and histochemistry of prostatic glands in relation to sex hormones. Int Rev Cytol
    87. The fine structure of the basal cell of human prostate.
    88. The Sca-1 cell surface marker enriches for a prostate-regenerating cell subpopulation that can initiate prostate tumorigenesis.
    89. The Sca-1 cell surface marker enriches for a prostate-regenerating cell subpopulation that can initiate prostate tumourigenesis.
    90. TMPRSS2–ETS fusion prostate cancer; biological and clinical implications.
    91. (1993). Widespread distribution of nuclear androgen receptors in the basal cell layer of the normal and hyperplastic human prostate. Virchows Arch Pathol Anat Histopathol
    92. Wnt/β-catenin signaling in cancer stemness and malignant behavior.
    93. β1 integrin deletion from the basal compartment of the mammary epithelium affects stem cells. N a tC e l lB i o l 2008;10:716–722.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.